Stifel lowered the firm’s price target on Inventiva (IVA) to $17 from $20 and keeps a Buy rating on the shares. The company removed its “biggest stock overhang” through an equity financing of up to EUR 348M in three tranches, the first of which was closed in October, the analyst tells investors. The firm, which notes cash is sufficient until Q2 of 2025 with access to future conditional tranches, reduced it price target to account for dilution.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on IVA:
- Inventiva’s Financial Position and Future Prospects
- Inventiva reports revenues for irst nine months FY24 EUR 1.3M
- Inventiva Reports Voting Rights and Advances Clinical Trials
- Inventiva Prepares for Key General Meeting and Financing Plans
- Inventiva’s Phase 2 Results Boost Hope for MASH Treatment
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
